Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential

5. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Number of Hedge Fund Holders as of Q4: 27

Tao Capital’s Equity Stake: $55,807

Upside Potential as of May 8: 23.92%

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is an American biotech company founded in 2008 by five MIT scientists, including CEO Jason Kelly. Headquartered in Boston, Massachusetts, Ginkgo Bioworks specializes in bioengineering and synthetic biology, primarily partnering with clients to develop bespoke microbes. The company’s revenue model involves upfront research fees, milestone payments, and royalties linked to the successful commercialization of engineered organisms.

For the first quarter ended March 31, 2025, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) reported total revenue of $48 million, marking a 27% increase from $38 million in the same period last year. This growth was primarily driven by an increase of $7 million in cell engineering revenue. Biosecurity revenue remained flat at $10 million year-over-year, reflecting stable demand within this segment. Notably, the company reported a GAAP net loss of $91 million, significantly reduced from a loss of $166 million in the first quarter of 2024. The improvement in financial performance was largely attributed to increased revenue and a strategic reduction in operating expenses, leading to an adjusted EBITDA of $(47) million, up from $(117) million in the prior-year period.

The company maintains a robust liquidity position, with cash, cash equivalents, and marketable securities totaling $517 million as of March 31, 2025. Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) issued its 2025 guidance, projecting total revenue between $167 million and $187 million, cell engineering revenue of $117 million to $137 million, and biosecurity revenue of at least $50 million.

Investor sentiment towards Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has grown stronger, with hedge fund interest increasing significantly. By the end of Q4 2024, 27 hedge funds tracked by Insider Monkey held stakes in the company, up from 17 in the previous quarter, with total holdings valued at $119 million. This uptick in institutional support underscores rising confidence in Ginkgo Bioworks’ growth prospects and its pioneering role in the synthetic biology sector.